Q4 2022 Results
Company overview
Financial review
Innovation: Pipeline overview
Novartis pipeline in Phase 3
Solid Tumors
Code
AAA617
2023 priorities
Appendix
Innovation: Clinical trials
Abbreviations
Hematology
8 lead indications
Lead indication
Mechanism
BCR-ABL inhibitor
Thrombopoietin receptor
(TPO-R) agonist
CFB inhibitor
Indication(s)
Chronic myeloid leukemia, 1st line
Radiation sickness syndrome
Paroxysmal nocturnal hemoglobinuria
Atypical hemolytic uraemic syndrome
Myelodysplastic syndrome
1L Immune Thrombocytopenia
2L Immune Thrombocytopenia
warm Autoimmune Hemolytic Anemia
Name
Mechanism
Indication(s)
Pluvicto™
Radioligand therapy target PSMA mCRPC, pre-taxane
Metastatic hormone sensitive prostate cancer (mHSPC)
AAA6011
LutatheraⓇ
BYL719
JDQ443
Piqray®
JDQ443
PI3Ka inhibitor
KRAS inhibitor
LEE011
Kisqali®
CDK4/6 Inhibitor
NIS793
NIS793
TGFB1 inhibitor
VDT482
tislelizumab
PD1 inhibitor
Radioligand therapy target SSTR Gastroenteropancreatic neuroendocrine tumors, 1st line in G2/3
tumors (GEP-NET 1L G3)
Ovarian cancer
2/3L Non-small cell lung cancer
HR+/HER2- BC (adj)
1L Metastatic pancreatic ductal adenocarcinoma
1L Nasopharyngeal Carcinoma
1L ESCC
Code
Name
ABL001
ScemblixⓇ
ETB115
PromactaⓇ
LNP023
iptacopan
MBG453
VAY736
sabatolimab
ianalumab
TIM3 antagonist
BAFF-R inhibitor
Adj/Neo adj. NSCLC
1L Gastric cancer
Immunology
1L Hepatocellular Carcinoma
1L Urothelial Cell Carcinoma
Code
Name
Mechanism
AIN457
Cosentyx®
IL17A inhibitor
IGE025
Xolair®
IgE inhibitor.
LOU064
remibrutinib
BTK inhibitor
OGE031 ligelizumab
VAY736
ianalumab
IgE inhibitor
BAFF-R inhibitor
Indication(s)
Lupus Nephritis
Giant cell arteritis
Food allergy
Chronic spontaneous urticaria
Food allergy
Sjögren's
Lupus Nephritis
Localized ESCC
1L Small Cell Lung Cancer
Cardiovascular
Mechanism
siRNA (regulation of LDL-C)
CFB inhibitor
Code Name
KJX839 Leqvio®
LNP023 iptacopan
TQJ230 pelacarsen
ASO targeting Lp(a)
Indication(s)
CVRR-LDLC
IgA nephropathy
Hyperlipidemia, pediatrics
C3 glomerulopathy
Secondary prevention of cardiovascular events in patients with
elevated levels of lipoprotein (a) (CVRR-Lp(a))
Others
Code
Name
Mechanism
Neuroscience
Code
Name
AMG334 AimovigⓇ
BAF312 Mayzent
LOU064 remibrutinib
OAV101 AVXS-101
OMB157 Kesimpta®
Mechanism
CGRPR antagonist
S1P1,5 receptor modulator
BTK inhibitor
Indication(s)
Migraine, pediatrics
Multiple sclerosis, pediatrics
Multiple sclerosis
SMN1 gene replacement therapy SMA IT administration
CD20 Antagonist
Global Health
COA566 Coartem®
Ophthalmology
RTH258 BeovuⓇ
Biosimilars
PGH-1 (artemisinin combination
therapy)
VEGF inhibitor
Mechanism
Code
Multiple sclerosis, pediatrics
Name
GP2411 denosumab
SOK583 aflibercept
anti RANKL mAb
VEGF inhibitor
1. 177 Lu-dotatate in US.
55 Investor Relations | Q4 2022 Results
Indication(s)
Malaria, uncomplicated (<5kg patients)
Diabetic retinopathy
Indication(s)
Osteoporosis (same as originator)
Ophthalmology indication (as originator)
U NOVARTIS | Reimagining MedicineView entire presentation